Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.53 |
| ▸ | CTSC | P53634 | 1/20 | 0.51 |
| ▸ | KHK | P50053 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2392383 | 1.00 | HPGD (0.56) | HPGDSCN3ASCN9APOLBPSMB8 | |
| SCHEMBL9352214 | 1.00 | HPGD (0.56) | HPGDSCN3ASCN9APOLBPSMB8 | |
| Hydrochloric Acid SCHEMBL4306381 | 0.98 | SCN3A (0.56) | HPGDSCN3ASCN9APOLBPSMB8 | |
| SCHEMBL516052 | 0.95 | HPGD (0.58) | HPGDSCN3ASCN9APOLBPSMB8 | |
| SCHEMBL13708499 | 0.95 | HPGD (0.58) | HPGDSCN3ASCN9APOLBPSMB8 | |
| Hydrochloric Acid SCHEMBL3266984 | 0.94 | HPGD (0.57) | HPGDSCN3ASCN9APOLBPSMB8 | |
| SCHEMBL7072835 | 0.91 | HPGD (0.56) | HPGDPOLBDPP4GAAMAPT | |
| SCHEMBL7072829 | 0.91 | HPGD (0.56) | HPGDPOLBDPP4GAAMAPT | |
| SCHEMBL1752153 | 0.91 | SCN3A (0.59) | HPGDSCN3ASCN9APSMB8CTSC | |
| SCHEMBL17676966 | 0.91 | SCN3A (0.59) | HPGDSCN3ASCN9APSMB8CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4604951-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | AMIRA THERAPEUTICS, S.L. (ES) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024083861-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | SELABTEC SCIENCES, SLU (ES) | 2024-04-25 | — | — | WO | disclosed |
| EP-4356909-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | Selabtec Sciences, SLU (ES) | 2024-04-24 | — | — | EP | disclosed |
| WO-2023073115-A1 | PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-3774722-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | Epiodyne, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019195634-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-05-03 | — | — | US | disclosed |
| US-8569507-B2 | N-(2-oxo-1-phenylpiperidin-3-yl)sulfonamides for the identification of biological and pharmacological activity | INSTITUT UNIV. DE CIENCIA I TECHNOLOGIA, S.A. (ES) | 2013-10-29 | — | — | US | disclosed |
| US-8455660-B2 | 1-(sulfonyl)-N-phenylpyrrolidine-2-carboxamides for the identification of biological and pharmacological activity | INSTITUT UNIV. DE CIENCIA I TECNOLOGIA, S.A. (ES) | 2013-06-04 | — | — | US | disclosed |
| US-8217204-B2 | Catalyst for asymmetric hydrogenation | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| WO-2001022966-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-05 | — | — | WO | disclosed |
| WO-2001004105-A1 | METHOD FOR PREPARING 2-(2-ARYLMORPHOLIN-2-YL)ETHANOL DERIVATIVES AND INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 2001-01-18 | — | — | WO | disclosed |
| EP-1001933-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006367-A1 | CASPASES AND APOPTOSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
| US-4636567-A | CNS DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1987-01-13 | — | — | US | disclosed |
| US-4610821-A | CENTRAL NERVOUS SYSTEM, THYROTROPIN RELEASING HORMONE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-09-09 | — | — | US | disclosed |
| US-4564609-A | NERVOUS SYSTEM DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-01-14 | — | — | US | disclosed |
| US-4562197-A | CATTLE, POULTRY | PFIZER INC. (US) | 1985-12-31 | — | — | US | disclosed |
| EP-0144230-A2 | Growth promotants for animals | Pfizer Limited (GB) | 1985-06-12 | — | — | EP | disclosed |
| EP-0123444-A1 | 4-Substituted-2-azetidinone compound, process of producing the compounds, and medicaments containing the compounds | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1984-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118721-A1 | PYRIMIDINE DERIVATIVES | MTHFD1, TYMS, DPYD | HPGD 391/4885SCN3A 4391/4885SCN9A 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.